Oxford GlycoSciences Plc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jongmans who started this subject	1/15/2003 3:09:45 AM
From: nigel bates	Read Replies (1) of 469

OXFORD, England, Jan. 15 /PRNewswire-FirstCall/ -- Oxford GlycoSciences Plc (Nasdaq: OGSI - News; LSE: OGS - News) has received notice from the European Patent Office that it intends to grant OGS a patent covering the fundamental platform technology it has developed for use in conducting proteomics research. The patent gives OGS proprietary rights to computer-assisted methods and apparatus for identifying and isolating biomolecules in a biological sample. The patent is expected to be granted in Q1 2003. Corresponding patents have already been granted to OGS in the US. David Ebsworth, Ph.D., CEO of OGS said, "This patent is an affirmation that OGS is at the forefront of innovation and excellence in proteomics research. It also presents the opportunity for additional revenue through licensing to pharmaceutical and other companies which utilize processes we have developed in their proteomics research."...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next